Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 7/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (-)-Gossypol Hexamethyl Ether SCHEMBL2622262 | 0.90 | AKR1B1 (0.55) | AKR1B1PDE3BPDE3A | |
| SCHEMBL2622244 | 0.87 | AKR1B1 (0.54) | AKR1B1 | |
| SCHEMBL10268835 | 0.82 | AKR1B1 (0.51) | AKR1B1 | |
| SCHEMBL22700467 | 0.80 | AKR1B1 (0.70) | AKR1B1 | |
| SCHEMBL2622254 | 0.76 | AKR1B1 (0.46) | AKR1B1 | |
| SCHEMBL2622263 | 0.66 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL2622259 | 0.64 | AKR1B1 (1.00) | AKR1B1PDE3BPDE3A | |
| SCHEMBL2622268 | 0.63 | AKR1B1 (0.60) | AKR1B1 | |
| SCHEMBL22700465 | 0.62 | AKR1B1 (0.47) | AKR1B1 | |
| SCHEMBL2622242 | 0.62 | AKR1B1 (0.39) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | GEORGETOWN UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | BCL2, BCL2L1, BCL2L2 | AKR1B1 1880/4885PDE5A 2647/4885PDE4A 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.